Our in vitro benefits advise that EAM-2201 need to be examined when it comes to possible in vivo pharmacokinetic drug–drug interactions attributable to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 functions and competitive inhibition of UGT1A3 activity. Outcome with the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, https://rogeri272tix5.wikimidpoint.com/user